MCID: PRT013
MIFTS: 59

Portal Hypertension

Categories: Rare diseases, Gastrointestinal diseases, Cardiovascular diseases, Endocrine diseases

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 12 76 53 29 15
Hypertension, Portal 53 44 73
Hypertension Portal 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10762
ICD10 33 K76.6
ICD9CM 35 572.3
MeSH 44 D006975
NCIt 50 C3119
SNOMED-CT 68 155821005 34742003
UMLS 73 C0020541

Summaries for Portal Hypertension

NIH Rare Diseases : 53 Portal hypertensionis abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. It may be caused by a variety of conditions, but cirrhosis is the most common cause in Western countries. Treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications.

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to esophageal varix and congenital hepatic fibrosis, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is DGUOK (Deoxyguanosine Kinase), and among its related pathways/superpathways are Signaling by GPCR and PEDF Induced Signaling. The drugs Spironolactone and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Portal hypertension is hypertension (high blood pressure) in the hepatic portal system – made up of the... more...

Related Diseases for Portal Hypertension

Diseases in the Portal Hypertension family:

Portal Hypertension Due to Infrahepatic Block

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 346)
# Related Disease Score Top Affiliating Genes
1 esophageal varix 32.6 ALB F2 SST
2 congenital hepatic fibrosis 32.1 AGTR1 PKHD1
3 hypersplenism 31.8 ALB F2 THPO
4 gastric antral vascular ectasia 31.3 CTC1 SST
5 hepatoportal sclerosis 30.9 F2 GPT
6 schistosomiasis 30.7 ALB F2 TNF
7 abdominal tuberculosis 30.7 ALB F2
8 thrombosis 30.5 F2 JAK2 VWF
9 liver disease 30.3 ALB F2 GPT TNF
10 hepatorenal syndrome 30.2 ALB EDN1 F2
11 hepatic coma 30.1 ALB F2 GPT
12 hepatic tuberculosis 29.9 ALB F2 GPT
13 cholelithiasis 29.9 ALB GPT SST
14 peritonitis 29.9 ALB F2 TNF
15 choledocholithiasis 29.9 ALB F2 GPT
16 hepatic encephalopathy 29.9 ALB F2 GPT TNF
17 acute liver failure 29.8 ALB F2 GPT
18 hepatitis b 29.8 ALB F2 GPT TNF
19 cholecystitis 29.8 ALB F2 GPT
20 nonalcoholic steatohepatitis 29.8 F2 GPT TNF
21 angiodysplasia 29.7 SST VEGFA VWF
22 alcoholic hepatitis 29.7 ALB F2 GPT TNF
23 cholangitis 29.7 ALB F2 GPT TNF
24 kidney disease 29.4 AGTR1 ALB EDN1 PKHD1 UTS2
25 active peptic ulcer disease 29.4 F2 VWF
26 viral hepatitis 29.3 ALB F2 GPT TNF
27 connective tissue disease 29.2 BMPR2 EDN1 EDNRA TNF
28 obstructive jaundice 29.1 ALB EDN1 F2 GPT TNF
29 autosomal dominant polycystic kidney disease 28.4 ALB EDN1 EDNRA NOS3 PKHD1 VEGFA
30 hepatic vascular disease 28.3 ALB EDN1 F2 JAK2 NOS3 SST
31 liver cirrhosis 28.3 ALB EDN1 F2 GPT SST THPO
32 hepatopulmonary syndrome 27.8 ALB EDN1 EDNRA NOS3 TNF VEGFA
33 pulmonary hypertension 26.9 BMPR2 EDN1 EDNRA NOS3 UTS2 VEGFA
34 diabetes mellitus, noninsulin-dependent 26.7 AGTR1 ALB EDN1 GPT NOS3 SST
35 vascular disease 26.4 ALB BMPR2 EDN1 F2 NOS3 TNF
36 portal hypertension, noncirrhotic 12.5
37 colonic varices without portal hypertension 12.1
38 portal hypertension due to infrahepatic block 12.1
39 nodular regenerative hyperplasia 11.9
40 banti's syndrome 11.6
41 splenomegaly 11.3
42 polycystic kidney disease 4 with or without polycystic liver disease 11.2
43 caroli disease 11.2
44 portal vein thrombosis 11.1
45 myelofibrosis 11.1
46 adams-oliver syndrome 1 11.0
47 budd-chiari syndrome 10.9
48 cerebroretinal microangiopathy with calcifications and cysts 1 10.9
49 cholangitis, primary sclerosing 10.9
50 antipyrine metabolism 10.8 ALB F2

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Failure
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:



Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:


signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 AGTR1 CTC1 ALB EDN1 BMPR2 EDNRA
2 growth/size/body region MP:0005378 10.29 AGTR1 CTC1 EDN1 BMPR2 EDNRA NOS3
3 hematopoietic system MP:0005397 10.27 AGTR1 CTC1 BMPR2 EDNRA NOS3 F2
4 immune system MP:0005387 10.27 AGTR1 CTC1 BMPR2 EDNRA NOS3 F2
5 cardiovascular system MP:0005385 10.26 AGTR1 EDN1 BMPR2 EDNRA NOS3 F2
6 cellular MP:0005384 10.25 BMPR2 CTC1 ALB JAK2 EDNRA NOS3
7 mortality/aging MP:0010768 10.25 AGTR1 CTC1 ALB EDN1 BMPR2 EDNRA
8 digestive/alimentary MP:0005381 10.24 ALB EDN1 EDNRA NOS3 F2 PKHD1
9 endocrine/exocrine gland MP:0005379 10.18 CTC1 ALB EDN1 EDNRA NOS3 PKHD1
10 nervous system MP:0003631 10.06 AGTR1 EDN1 BMPR2 EDNRA NOS3 F2
11 liver/biliary system MP:0005370 9.98 ALB NOS3 PKHD1 JAK2 VEGFA TNF
12 normal MP:0002873 9.96 ALB EDN1 BMPR2 EDNRA NOS3 F2
13 muscle MP:0005369 9.91 BMPR2 ALB EDN1 EDNRA NOS3 VEGFA
14 renal/urinary system MP:0005367 9.76 AGTR1 ALB EDN1 BMPR2 EDNRA NOS3
15 respiratory system MP:0005388 9.5 BMPR2 EDNRA NOS3 F2 PKHD1 VEGFA
16 skeleton MP:0005390 9.32 EDN1 BMPR2 EDNRA NOS3 F2 GPT

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4,Phase 2,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
3
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 10102-43-9 145068 160954
4
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
5
Prazosin Approved Phase 4 19216-56-9 4893
6
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
7
Carvedilol Approved, Investigational Phase 4,Phase 3,Not Applicable 72956-09-3 2585
8
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
9
Nadolol Approved Phase 4,Phase 3,Not Applicable 42200-33-9 39147
10
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
11
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
12
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
13
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 54-31-9 3440
14
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
15
Warfarin Approved Phase 4,Phase 3,Not Applicable 81-81-2 6691 54678486
16
Terlipressin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 14636-12-5 72081
17
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
18
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
19
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
20
Lactulose Approved Phase 4,Phase 2,Not Applicable 4618-18-2 11333
21
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83150-76-9 383414 6400441
22 Nadroparin Approved, Investigational Phase 4,Not Applicable 9041-08-1
23
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
24
Dipyridamole Approved Phase 4 58-32-2 3108
25
Dalteparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6
26
Peginterferon alfa-2b Approved Phase 4,Phase 3 99210-65-8, 215647-85-1
27
Tranexamic Acid Approved Phase 4 1197-18-8 5526
28
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
29
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
30
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
31 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
32 isosorbide-5-mononitrate Phase 4,Not Applicable
33 rifamycin SV Phase 4,Phase 3,Phase 2
34 diuretics Phase 4,Phase 2,Phase 3,Not Applicable
35 Respiratory System Agents Phase 4,Phase 2
36 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Rifamycins Phase 4,Phase 3,Phase 2
38 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
39 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Not Applicable
40 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
41 Adrenergic alpha-Antagonists Phase 4,Phase 3,Not Applicable
42 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 3
43 Mineralocorticoids Phase 4,Phase 2,Phase 3
44 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
45 Adrenergic beta-Agonists Phase 4,Phase 2
46 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
47 Mydriatics Phase 4,Phase 2
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Natriuretic Agents Phase 4,Phase 2,Phase 3,Not Applicable
50 Coagulants Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 258)
# Name Status NCT ID Phase Drugs
1 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
2 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
3 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
4 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
5 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
6 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
7 Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
8 Preventing Recurrent Bleeding After Eradication of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
9 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
10 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
11 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
12 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
13 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
14 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
15 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Completed NCT02994485 Phase 4 Simvastatin
16 Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
17 Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
18 Secondary Prophylaxis After Variceal Bleeding in Non-Responders Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
19 Short Course Terlipressin for Control of Acute Variceal Bleeding Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
20 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
21 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
22 Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
23 The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed Completed NCT00534677 Phase 4 Terlipressin;Octreotide
24 Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites. Completed NCT00968695 Phase 4 Albumin
25 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Recruiting NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
26 Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis Recruiting NCT02907749 Phase 4 Spironolactone;Carvedilol
27 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
28 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
29 Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Not yet recruiting NCT02945956 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu
30 Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Traditional Chinese Medicine and Entecavir Not yet recruiting NCT02945982 Phase 4 Entecavir+Carvedilol+ Placebo;Entecavir+Carvedilol+ Fuzheng Huayu;Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis
31 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
32 Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
33 Sodium Restriction in the Management of Cirrhotic Ascites Terminated NCT00548366 Phase 4
34 ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Unknown status NCT01560845 Phase 2, Phase 3
35 Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
36 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
37 Probiotics for Portal Hypertension Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
38 Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
39 Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC Unknown status NCT02338297 Phase 3 EGM;PVA
40 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
41 ¹³C-Methacetin Breath Test (MBT) Methodology Study Unknown status NCT01205074 Phase 2, Phase 3 Non selective beta blocker - Propranolol
42 Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH) Completed NCT01000779 Phase 3 Propranolol
43 Simvastatin Effect on Portal Hypertension Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
44 Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
45 Danish Carvedilol Study in Portal Hypertension Completed NCT00493480 Phase 3 carvedilol;propranolol
46 Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
47 Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
48 Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope Completed NCT01131962 Phase 3
49 Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS Completed NCT02016196 Phase 3 Rifaximin;placebo
50 Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Completed NCT01654731 Phase 3 Bezafibrate;placebo

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

# Genetic test Affiliating Genes
1 Portal Hypertension 29

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

41
Liver, Spleen, Endothelial, Testes, Brain, Kidney, Bone

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 1107)
# Title Authors Year
1
Use of Iodized Oil and Gelatin Sponge Embolization in Splenic Artery Coiling Reduces Bleeding from Laparoscopic Splenectomy for Cirrhotic Portal Hypertension Patients with Complicating Hypersplenic Splenomegaly: A Comparative Study. ( 29608435 )
2018
2
Torsion of a wandering spleen as a cause of portal hypertension and mesenteric varices: a rare aetiology. ( 29876050 )
2018
3
Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? Author's reply. ( 29341273 )
2018
4
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension. ( 29970660 )
2018
5
Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. ( 29781346 )
2018
6
Impact of patatin-like phospholipase domain containing 3 rs738409A G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. ( 29956823 )
2018
7
Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. ( 29326427 )
2018
8
Beneficial Effects of the Peroxisome Proliferator-Activated Receptor I+/I^ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension. ( 29929914 )
2018
9
Managing portal hypertension in patients with liver cirrhosis. ( 29780579 )
2018
10
The "caput medusae" sign in portal hypertension. ( 29450607 )
2018
11
Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. ( 29391766 )
2018
12
Liver stiffness better predicts portal hypertension after HCV eradication. ( 29922768 )
2018
13
Doppler assessment of children with liver cirrhosis and portal hypertension in comparison with a healthy control group: An analytical cross-sectional study. ( 29937902 )
2018
14
Endoscopic linear stapler-assisted resection of a giant solid pseudopapillary pancreatic tumor with concurrent regional portal hypertension: a case report. ( 29865921 )
2018
15
Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? ( 29341272 )
2018
16
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. ( 29977287 )
2018
17
Periampullary Variceal Bleeding: An Atypical Complication of Portal Hypertension. ( 29854492 )
2018
18
Portal hypertension and hypersplenism in extrahepatic portal venous obstruction: Are they related? ( 29936618 )
2018
19
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
20
Bleeding stomal varices in portal hypertension. ( 29904472 )
2018
21
Refractory Hepatic Hydrothorax: A Rare Complication of Systemic Sclerosis and Presinusoidal Portal Hypertension. ( 29854501 )
2018
22
Editorial: the portal hypertension puzzle-spleen stiffness evades validation as non-invasive marker of clinically significant portal hypertension. ( 29446131 )
2018
23
Ten-year experience of transjugular intrahepatic portosystemic shunt for noncirrhotic portal hypertension. ( 29324586 )
2018
24
TMEM16A regulates portal vein smooth muscle cell proliferation in portal hypertension. ( 29434696 )
2018
25
Portal Hypertension in a Patient With Recurrent Pancreatic Cancer After Radiotherapy and Systemic Chemotherapy. ( 29743803 )
2018
26
Letter: high oral dose of taurine for portal hypertension in cirrhotic patients-some clinical pharmacology considerations. ( 29446135 )
2018
27
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. ( 29377193 )
2018
28
Ectopic varices: a potential cause of gastrointestinal bleeding in patients with portal hypertension. ( 29909391 )
2018
29
APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure. ( 29274906 )
2018
30
Non-cirrhotic portal hypertension: A possibly benign but complicated disease. ( 29935993 )
2018
31
Massive Epithelioid Hemangioendothelioma Causing Noncirrhotic Portal Hypertension. ( 29609064 )
2018
32
Laparoscopic splenectomy and subsequent oncologic gastric surgery in cirrhotic patients with portal hypertension and hypersplenism. ( 29391322 )
2018
33
Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. ( 29322599 )
2018
34
Intentional Modulation of Portal Venous Pressure by Splenectomy Saves the Patient with Liver Failure and Portal Hypertension After Major Hepatectomy: Is Delayed Splenectomy an Acceptable Therapeutic Option for Secondary Portal Hypertension? ( 29410393 )
2018
35
Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. ( 29368385 )
2018
36
Surveillance for portal hypertension in the course of liver cirrhosis. ( 29904721 )
2018
37
Point Shear Wave Elastography of the Spleen: Its Role in Patients with Portal Hypertension. ( 29352618 )
2018
38
Portal Hypertensive Colopathy with Pelvic Varices presenting as Severe Lower GI Bleed treated with TIPSS. ( 29952445 )
2018
39
Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution. ( 29449343 )
2018
40
Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients. ( 29900587 )
2018
41
Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. ( 29858640 )
2018
42
Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. ( 29429910 )
2018
43
Combined caesarean with splenectomy in pregnancy with portal hypertension: defining plausibility. ( 28918404 )
2017
44
Cholecystolithotomy Combined Armillarisin A versus Cholecystectomy in Cirrhotic Portal Hypertension Patients with Symptomatic Cholelithiasis. ( 28463673 )
2017
45
Unsuccessful transjugular intrahepatic portosystemic shunt for a patient with right heart failure and portal hypertension. ( 29364100 )
2017
46
Detailed EFSUM recommendations on the scope of ultrasound assessment in patients with portal hypertension considering the diagnostic reference level. ( 28856019 )
2017
47
Elastography methods for the non-invasive assessment of portal hypertension. ( 28856972 )
2017
48
Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. ( 28824317 )
2017
49
Polycystic Liver Disease and Sarcoidosis: Unusual Coexisting Etiologies of Portal Hypertension. ( 28280650 )
2017
50
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension. ( 28855918 )
2017

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 AGTR1 BMPR2 EDN1 EDNRA F2 JAK2
2
Show member pathways
13.48 BMPR2 EDN1 EDNRA F2 JAK2 NOS3
3
Show member pathways
13.28 AGTR1 F2 JAK2 THPO TNF UTS2
4
Show member pathways
13.05 ALB F2 JAK2 NOS3 THPO VEGFA
5
Show member pathways
12.69 AGTR1 EDN1 F2 JAK2 NOS3 TNF
6
Show member pathways
12.25 AGTR1 F2 JAK2 NOS3 TNF
7 11.78 JAK2 TNF VEGFA
8 11.7 EDN1 NOS3 VEGFA
9
Show member pathways
11.68 F2 THPO VWF
10 11.5 BMPR2 EDN1 NOS3 TNF VEGFA
11 11.31 EDN1 NOS3 VEGFA
12 11.27 EDN1 EDNRA JAK2
13 11.1 AGTR1 EDN1 JAK2 NOS3 TNF VEGFA
14 10.96 EDN1 EDNRA NOS3
15
Show member pathways
10.81 EDN1 JAK2 VEGFA

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 ALB EDN1 F2 SST THPO TNF
2 caveola GO:0005901 9.5 BMPR2 JAK2 NOS3
3 platelet alpha granule lumen GO:0031093 9.43 ALB VEGFA VWF
4 extracellular space GO:0005615 9.32 ALB BMPR2 EDN1 F2 GPT SST
5 Weibel-Palade body GO:0033093 8.96 EDN1 VWF

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 EDN1 F2 JAK2 PKHD1 VEGFA
2 regulation of cell proliferation GO:0042127 9.87 AGTR1 BMPR2 JAK2 TNF
3 positive regulation of DNA binding transcription factor activity GO:0051091 9.78 EDN1 JAK2 TNF
4 in utero embryonic development GO:0001701 9.78 EDN1 EDNRA NOS3 VEGFA
5 kidney development GO:0001822 9.77 AGTR1 PKHD1 VEGFA
6 regulation of inflammatory response GO:0050727 9.76 AGTR1 JAK2 TNF
7 positive regulation of MAP kinase activity GO:0043406 9.7 EDN1 TNF VEGFA
8 positive regulation of protein phosphorylation GO:0001934 9.67 F2 THPO TNF VEGFA
9 regulation of blood vessel diameter GO:0097746 9.59 AGTR1 UTS2
10 positive regulation of endothelial cell migration GO:0010595 9.58 BMPR2 EDN1 VEGFA
11 artery smooth muscle contraction GO:0014824 9.56 EDN1 EDNRA
12 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 AGTR1 EDN1 EDNRA JAK2
13 negative regulation of platelet activation GO:0010544 9.55 F2 NOS3
14 endothelial cell apoptotic process GO:0072577 9.54 BMPR2 TNF
15 positive regulation of axon extension involved in axon guidance GO:0048842 9.51 BMPR2 VEGFA
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 EDN1 JAK2 TNF
17 regulation of glucose transmembrane transport GO:0010827 9.49 EDN1 EDNRA
18 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.43 EDN1 NOS3
19 branching involved in blood vessel morphogenesis GO:0001569 9.33 EDN1 EDNRA VEGFA
20 regulation of blood pressure GO:0008217 9.26 EDN1 EDNRA NOS3 UTS2
21 regulation of signaling receptor activity GO:0010469 9.17 EDN1 F2 SST THPO TNF UTS2
22 G-protein coupled receptor signaling pathway GO:0007186 10 AGTR1 EDN1 EDNRA F2 JAK2 SST

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 EDN1 THPO TNF VEGFA
2 hormone activity GO:0005179 8.92 EDN1 SST THPO UTS2

Sources for Portal Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....